AlphAIAlphAI — Financial news for AI agents
gurufocus.comOCT 212 min read$ABT

Abbott Laboratories (ABT) Reports Q3 Earnings Beat, Reaffirms 20

Abbott Laboratories (ABT) reported Q3 non-GAAP EPS of $1.42, beating estimates by $0.01, with revenue of $13.01B, up 14.4% YoY. The company reaffirmed its 2026 adjusted EPS guidance of $5.50–$5.55. ABT's dividend yield is 2.59% with a 80% payout ratio, and its GF Score™ is 82/100, indicating strong financial health.

Original reporting
gurufocus.com
Published Oct 21, 2026, 11:57 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ABT
Bullish
high confidence
Mentioned
$ABT
Relevance
8/10
AlphAI data visualization · based on gurufocus.com
Decision brief

The 30-second read

$ABTBullishHigh
01

Why it matters

The earnings beat reinforces the company's growth narrative and may attract dividend‑seeking investors, while the high payout ratio warrants monitoring.

02

Market read

First‑report earnings beat for a large‑cap health‑care stock; likely short‑term upside.

03

What to watch

Insider net selling and mixed guru activity suggest some caution despite the beat.

Relevance 8/10Novelty 9/10Timing: pre‑market today

Background

Abbott Laboratories is a $177 B diversified health‑care company with segments in medical devices, diagnostics, pharmaceuticals, and nutrition.

Company-level read

Ticker impact

$ABTBullishHigh confidence
Context

Abbott reported Q3 non‑GAAP EPS of $1.42 beating estimates and revenue of $13.01 B, reaffirming FY2026 EPS guidance of $5.50‑$5.55.

Expected impact

likely upward pressure as the market prices in the earnings beat and reaffirmed guidance

Evidence & confidence

The beat is fresh, the company is large‑cap, and guidance remains unchanged, reducing downside risk.

Market effects

Sector

Healthcare sector may see modest rally as a leading diversified health‑care name posts a beat.

Regional

U.S. equities could open higher on the earnings surprise.

Global

Limited; primarily affects U.S. and global health‑care investors.

Counterpoint

What could challenge this read

The high 80% dividend payout ratio could constrain future dividend growth, tempering enthusiasm.

Key entities

  • company
    Abbott Laboratories

    U.S.-listed health‑care conglomerate (ticker ABT).

Read at source← All news

StoryAbbott reports Q3 2026 earnings, tightens FY EPS guidance and announces Nutrition unit spin‑off

Also covered by

5 outlets

Related articles

OCT 21
$ABTMed

Abbott Labs to Carve Out Nutrition Business Into Independent Company -- Update

Abbott Laboratories (ABT) plans to spin off its nutrition business, which generates $8.5B in annual sales, into an independent company by late 2027. The new entity will include brands like Pedialyte and Similac, led by Daniel Salvadori. Abbott shares fell 3.9% premarket. The move aims to focus Abbott's core portfolio on medical devices and diagnostics, with no expected impact on 2026 or 2027 guidance.

marketscreener.com2 min
OCT 21
$ABTHigh

Abbott to Carve Out Nutrition Business Into Independent Company

Abbott Laboratories plans to separate its nutrition business, generating $8.5B in annual sales, into an independent company by late 2027. Shares fell 3.9% premarket. The new company will include brands like Pedialyte and Similac, led by Daniel Salvadori. Abbott expects to incur one-time charges and maintain 2026 guidance. Post-separation, Abbott's sales will be around $42B.

finance.yahoo.com2 min
OCT 21
$ABTHighAI 8/10

Why is Abbott Laboratories stock down today?

Abbott Laboratories (ABT) stock fell 4.5% in pre-market trading after reporting Q3 2026 earnings that met profit expectations but announced plans to spin off its Nutrition segment, which generates $8.5B in annual sales. The company's adjusted EPS guidance remained unchanged. The broader market was up slightly, indicating the selloff was company-specific. ABT stock is down 16% year-to-date.

investing.com2 min
OCT 21
$ABTMedAI 8/10

Abbott (ABT) Reports Q3 Revenues Slightly Above Expectations, Re

Abbott Laboratories (ABT) reported Q3 revenues of $13.01B, slightly above analysts' expectations of $12.99B. The company highlighted balanced growth across its healthcare segments and a strong product pipeline. ABT offers a 2.59% dividend yield with a 80% payout ratio and a 7.7% 3-year dividend growth rate. The stock is trading 24.5% below its GF Value of $135.69, suggesting potential upside. Abbott's GF Score is 82/100, indicating solid fundamentals.

gurufocus.com3 min